The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Requirements: BS/BA degree in life sciences, finance, business or similar field and 8+ years of business development, venture capital, investment research, investment banking, corporate development or related experience; 2+ years of biotechnology/pharmaceutical in scientific based role preferred OR.